申请人:Elbaum Daniel
公开号:US20050107374A1
公开(公告)日:2005-05-19
The present invention relates to hydroxybenzimidazole pyrimidines or pyridines or pharmaceutically-acceptable salts thereof. Also included is a method of treatment of inflammation, inhibition of T cell activation and proliferation, arthritis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, organ transplant, acute transplant or heterograft or homograft rejection, transplantation tolerance induction, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, including ulcerative colitis, Crohn's disease, lupus, contact hypersensitivity, delayed-type hypersensitivity, and gluten-sensitive enteropathy, type 1 diabetes, psoriasis, contact dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune polyglandular disease, autoimmune alopecia, pernicious anemia, vitiligo, autoimmune hypopituatarism, Guillain-Barre syndrome, glomerulonephritis, serum sickness, uticaria, allergic diseases, asthma, hayfever, allergic rhinitis, scleracielma, mycosis fungoides, dermatomyositis, alopecia areata, chronic actinic dermatitis, eczema, Behcet's disease, Pustulosis palmoplanteris, Pyoderma gangrenum, Sezary's syndrome, atopic dermatitis, systemic schlerosis, morphea, atopic dermatitis, colon carcinoma or thymoma in a mammal comprising administering a therapeutically-effective amount a compound as described above.
本发明涉及羟基苯并咪唑嘧啶或吡啶或其药学上可接受的盐。还包括一种治疗炎症、抑制T细胞活化和增殖、关节炎、类风湿性关节炎、银屑病性关节炎、骨关节炎、器官移植、急性移植或异种移植或同种移植排斥、移植耐受诱导、缺血或再灌注损伤、心肌梗死、中风、多发性硬化症、炎症性肠病,包括溃疡性结肠炎、克罗恩病、狼疮、接触性超敏反应、迟发型超敏反应和对谷蛋白敏感性肠病、1型糖尿病、银屑病、接触性皮炎、桥本氏甲状腺炎、干燥综合征、自身免疫性甲状腺功能亢进症、阿迪森病、自身免疫性多腺体病、自身免疫性脱发、恶性贫血、白癜风、自身免疫性下丘脑功能减退症、格林-巴利综合征、肾小球肾炎、血清病、荨麻疹、过敏性疾病、哮喘、花粉热、过敏性鼻炎、硬皮病、真菌病、皮肌炎、斑秃、慢性光化性皮炎、湿疹、Behcet病、掌跖角化症、脓疱性荨麻疹、塞萨里综合征、特应性皮炎、系统性硬化症、硬皮病、特应性皮炎、哺乳动物的结肠癌或胸腺瘤,包括上述化合物的治疗有效量的给药方法。